AVAX Technologies, Inc. (AVAX) is a development stage biotechnology company specializing in the development and future commercialization of individualized vaccine therapies and other technologies for the treatment of cancer. The Company's vaccine consists of autologous (the patient’s own) cancer cells that have been treated with a chemical (haptenized) to make them more visible to the patient’s immune system. AVAX refer to its cancer vaccine technology as autologous cell vaccine immunotherapy and to the vaccine as the AC Vaccine. Its clinical trials for the AC Vaccine have concentrated on melanoma, ovarian carcinoma, which are its primary indications, and non-small cell lung cancer. The Company refers to its AC Vaccine candidates as: M-Vax, L-Vax and O-Vax. M-Vax is for the treatment of melanoma. L-Vax is for the treatment of non-small cell lung cancer. O-Vax is for the treatment of ovarian cancer.
Currently trading at 0.0770.
Related article: Melanoma Drug Called a “Breakthrough” After Study
This company will most likely be out of business by the end of the
ReplyDeleteyear.
We presently anticipate that our current cash resources will be
sufficient to fund operations through May 2008, assuming that we
significantly slow our current development plans until we raise
additional capital. We are targeting to raise between $10.0 million
and $25.0 million in this offering. If we are able to raise only $10.0
million, we will have cash resources to implement the development plan
for M-Vax, as discussed under "Plan of Operation" to the second
quarter of 2009, but would not have sufficient resources to commence
the Phase I-II trial for O-Vax or to continue the current Phase I-II
trial for L-Vax. Even if we are able to raise the full $25.0 million,
those funds and our existing cash resources will only allow us to
implement our plan of operation through the second half of 2010. In
addition, we have only a limited ability to generate revenues from
operations, and any revenues we generate are almost certain to be
substantially less than our operating expenses. Accordingly, whether
we raise only $10.0 million or $25.0 million in this offering, it will
be necessary to raise additional equity capital in 2009 or 2010 to
implement fully our plan of operation. Because of our limited cash and
financial resources, unless we are successful in raising additional
capital in this offering, our ability to continue as a going concern
beyond the second quarter of 2008 is in question.
http://www.sec.gov/Archives/edgar/data/1015441/000089710108000276/avax080519_s1.htm
So what? Look at what happened with VRMLQ. They were going BK and now it's over $10 PPS. If you can't afford to spend money on a cheap stock like AVAX you shouldn't be investing. There's no sure thing with stocks.
ReplyDeleteMy man what is your openion on OGNg
ReplyDeleteI'm not invested in OGNG and haven't really looked at it. I went to their site and did some poking around. Off-hand, it seems to be a decent bet. I see there issued some news in Sept. about targeting the China market. The food production production industry is really unknown to me, my man. What price did you get in at?
ReplyDelete